Skip to main content

Table 2 Association between cytokine expression and presence of active disease in patients with SLE

From: Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations

  Unadjusted Adjusted for age and gender Fully adjusteda
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
IL-21b 1.06 (0.99, 1.13) 0.081 1.08 (0.99, 1.17) 0.077 1.06 (0.95, 1.18) 0.326
CXCL13b 1.07 (0.97, 1.18) 0.178 1.08 (0.97, 1.19) 0.177 1.05 (0.94, 1.18) 0.385
BLySb 1.38 (0.96, 1.98) 0.079 1.58 (1.03, 2.42) 0.037 1.20 (0.82, 1.77) 0.350
IL-10 1.07 (1.01, 1.13) 0.013 1.08 (1.02, 1.14) 0.009 1.04 (0.99, 1.10) 0.143
IFNαb 1.27 (0.98, 1.64) 0.069 1.30 (0.99, 1.71) 0.056 1.14 (0.88, 1.48) 0.330
IL-18b 1.20 (1.05, 1.37) 0.009 1.25 (1.06, 1.47) 0.007 1.18 (0.98, 1.43) 0.075
PTX3c 1.33 (1.13, 1.56) 0.001 1.29 (1.11, 1.50) 0.001 1.23 (1.04, 1.46) 0.013
CXCL10 1.00 (1.00, 1.02) 0.022 1.01 (1.00, 1.02) 0.003 1.02 (1.00, 1.03) 0.008
IL-17 1.07 (1.01, 1.13) 0.020 1.06 (1.00, 1.13) 0.062 1.03 (0.98, 1.09) 0.279
MCP-1b 1.16 (1.00, 1.36) 0.056 1.20 (0.99, 1.45) 0.070 1.13 (0.90, 1.41) 0.294
  1. Logistic regression models to show the odds of having active disease for every 1 pg/ml increase in the concentration of cytokine
  2. SLE systemic lupus erythematosus, OR odds ratio, 95% CI 95% confidence intervals, CXCL chemokine (C-X-C motif) ligand, BLyS B lymphocyte stimulator, IFNα interferon alpha, PTX pentraxin-related protein, MCP monocyte chemotactic protein
  3. aModel adjusted for age, gender, disease duration, ethnicity (Caucasian vs non-Caucasian) and current steroid use
  4. bPer 100 pg/ml increase
  5. cPer 1000 pg/ml increase